Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06469138 Completed - COVID-19 Clinical Trials

A Phase 1 Study to Investigate 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects

Start date: August 2, 2022
Phase: Phase 1
Study type: Interventional

The aims of this Study are to determine: - How much of the Study Drug (bemcentinib) ends up in urine and faeces - How much of the Study Drug and its breakdown products get into the bloodstream - The breakdown products (metabolites) of the Study Drug - The safety of the Study Drug and any side effects that might be associated with it.

NCT ID: NCT06468761 Completed - Covid19 Clinical Trials

2-year Mortality After COVID-19 in Nursing Home Residents

Start date: May 11, 2020
Study type: Observational

This was a retrospective study conducted in three Nursing Homes (NHs). Residents who had survived the 1st CoPW (March to May 2020) were included. The diagnosis of COVID-19 was based on the results of a positive reverse transcriptase-polymerase chain reaction test. The collected data also included age, sex, length of residence in the NH, disability status, legal guardianship status, nutritional status, need for texture-modified food, hospitalization or Emergency Department visits during lockdown and SARS-COV2 vaccination status during the follow-up. Non-adjusted and adjusted Cox models were used to analyse factors associated with 2-year post-1stCoPW mortality.

NCT ID: NCT06468722 Completed - Clinical trials for Post-COVID-19 Syndrome

Fat Oxidation Capacity in Patients With Post Covid-19 Syndrome

Start date: April 1, 2021
Study type: Observational

Post-COVID-19 Syndrome (PCS) is characterized by symptoms, including fatigue, reduced physical performance, dyspnea, cognitive impairment, and psychological distress. The mechanisms underlying the onset and severity of PCS point to mitochondrial dysfunction as significant contributor. This study examined fat oxidation as a function of mitochondrial capacity during exercise.

NCT ID: NCT06463106 Completed - Long COVID Clinical Trials

Endothelial Dysfunction in Post-infection Fatigue Syndromes

Start date: June 1, 2021
Study type: Observational

Post-infection chronic fatigue syndromes, such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-COVID-19 condition (Long Covid), are conditions primarily characterized by debilitating fatigue. This fatigue can range from mild, where patients are still able to participate in some social activities (e.g., school, work), to moderate and severe, where sufferers are predominantly homebound and bedridden. As a result, ME/CFS and Long Covid not only negatively impact the quality of life of affected individuals and their caregivers but also represent a substantial and often silent burden on healthcare systems worldwide, including Austria. This is primarily because most cases remain undiagnosed due to the lack of standardized clinical assessments and diagnostic markers. Endothelial dysfunction, which is well known to affect blood flow, oxygen and nutrient delivery, and waste removal in the body, has been described as one of the key factors behind the symptoms experienced by ME/CFS and Long Covid patients. However, the mechanisms that might explain the development of endothelial dysfunction remain largely unexplored. Therefore, this project aims to evaluate key biological aspects related to the function of endothelial cells - a layer of cells lining blood vessels - using plasma samples from an Austrian cohort of ME/CFS and Long Covid patients. We expect that the findings from our study will provide new insights to better understand endothelial dysfunction in post-infection chronic fatigue syndromes, leading to improved patient stratification and tailored treatment alternatives.

NCT ID: NCT06460753 Completed - Clinical trials for Coronavirus Infection COVID-19

Analysis of Laboratory Markers for Severe COVID-19

Start date: April 10, 2024
Study type: Observational

The course of coronavirus infection was often severe and required hospitalization of patients in the intensive care unit. The new SARS-Cov-2 has been poor studied, so relatively reliable markers are needed to effectively monitor patients and predict complications and outcome. Taking into account the known mechanisms of pathogenesis, the biochemical markers as ferritin, procalcitonin, C-reactive protein and D-dimer were chosen for this purpose. Patients were divided according to the degree of pulmonary infiltration. We hypothesized that the markers would correlate with dynamics, complications, and outcomes.

NCT ID: NCT06452108 Completed - COVID-19 Clinical Trials

Community Perception on COVID-19 Prevention and Control

Start date: April 4, 2020
Study type: Observational

In times whereby COVID-19 is rapidly spreading, research on the epidemiological, diagnostic, clinical and social aspects of the illness has been highlighted as important as there is very limited information of this disease in all these aspects. Keeping this in view, WHO has published a roadmap for global research referred to as the 2019 novel Coronavirus Global research and innovation forum: towards a research roadmap13. This document has identified around 34 knowledge gaps which need to be addressed in order to learn more about this illness. One of these gaps indicates that disease transmission is driven by both social and biological factors. Social sciences research, thus, can play a very important role in combating this illness. It can bring rich insights into social, behavioral and contextual aspects of communities, societies and populations affected by COVID-19 to enhance acceptability of and adherence to evidence-based public health measures for successful infection prevention and control (IPC).

NCT ID: NCT06452056 Completed - SARS-CoV2 Infection Clinical Trials


Start date: January 7, 2021
Study type: Observational

The SARS-CoV-2 BioMedomics Rapid Antigen Screening Test (COV-SCAN) is an at-home rapid antigen COVID-19 antigen screening test device. The primary objectives of this study are to 1) Evaluate the clinical performance of COV-SCAN; 2.) Assess the usability of COV-SCAN and the paired app as an over-the-counter product to be used by lay persons in non- laboratory settings. The clinical performance and usability data will be submitted as part of an application for Emergency Use Authorization (EUA) to the FDA. 3) Assess acceptability and feasibility of the COV-SCAN test, paired app, and frequent testing regimen in demonstration projects in university and workforce settings.

NCT ID: NCT06444893 Completed - COVID-19 Clinical Trials

Morphofunctional Analysis and Gene Expression of Inflammation Molecules and Response Mechanisms to Oxidative Stress in Kidney Tissue of Deceased Patients With SARS-CoV-2 Virus Infection: "Ancestral Variant"

Start date: March 30, 2020
Study type: Observational

The involvement of the kidneys in patients infected with the SARS-CoV-2 virus at the outset of the pandemic was associated with high mortality rates worldwide. This was in part due to the generation of an inflammatory process and exacerbated oxidative stress. The present study was initiated to investigate the relationship between morphofunctional changes and gene expression in the kidney tissue of deceased Mexican patients prior to the initiation of vaccination. The investigator designed a single-center, prospective, cohort study, to analyze and relate the morphofunctional changes and gene expression of inflammatory and oxidative stress molecules in the kidney tissue of men who died from severe COVID-19. A total of 40 percutaneous renal biopsies from deceased patients with SARS-CoV-2 infection were included in the study and divided into two a groups. One group was preserved in trizol to obtain RNA and total protein, while the remaining sample was fixed in formalin to be examined by staining with hematoxylin and eosin. The histopathological analysis was conducted by an experienced nephropathologist. The expression of molecules was evaluated by real-time PCR (nphs2, slc9a1, cx3cl1, havcr1, slc22a17, sod2, egf, timp2, hmox1, fabp1, and so forth). The following biomarkers were analyzed: IL-6, Arg-1, DPP4, GSTT1, GGT1, OCL, CYP3A4, and CL-8. Additionally, Western blot analysis was conducted on claudins-5, occludin, HSP70, NRF-2, SOD2, NQO1, γ-GCL, and RAGE. The estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI (2021) equation, with the subjects divided into two groups based on their eGFR: >60 or <60 ml/min/1.73 m². The statistical analysis was conducted using the Stata program and GraphPad Prism software.

NCT ID: NCT06439134 Completed - COVID-19 Clinical Trials

Evaluation Of The Chronic Effects Of Covıd-19 Infection On The Respiratory System

Start date: June 1, 2022
Study type: Observational [Patient Registry]

The aim of this study is to evaluate whether there are chronic effects in the pulmonary system and systemic level in individuals in the post COVID19 period in order to elucidate the involvement of inflammation after recovery. In addition, a perspective on the utility of pulmonary function testing and pulmonary ultrasound in the evaluation of chronic effects and patient follow-up will is aimed to be provided. By measuring the protein levels of inflammatory markers along with the data abovementioned, a foresight regarding the long-term effects of the previous infection at both functional and immunological levels will be obtained, allowing us to evaluate the post-COVID period from different angles. Volunteers who recovered from COVID-19 and those who didn't have COVID-19 were compared by evaluating chest x-ray scores (CXR), lung ultrasound scores (LUSS), pulmonary function tests and inflammatory cytokine levels (TNF-α, IL-1, IL-6, IL-17A).

NCT ID: NCT06437210 Completed - COVID-19 Clinical Trials

Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome

Start date: February 15, 2022
Phase: N/A
Study type: Interventional

Reports of long-lasting symptoms of COVID-19 are increasing, but little is known about the prevalence of risk factors or whether it is possible to predict a prolonged course at disease onset. Prolonged COVID is characterized on the basis of symptoms such as fatigue, headache, dyspnea, and anosmia present for weeks, with older age, high body mass index, and female sex being more susceptible. Accordingly, and in the absence of specific treatments, the present study seeks to establish a treatment protocol for Post-COVID syndrome through the application of the dietary supplement VIUSID, due to its anti-inflammatory and immunomodulatory effect, thus helping to reduce and/or control the symptoms of the syndrome.